Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Athira Pharma, Inc. (ATHA) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Athira Pharma, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1620463.
Total stock buying since 2020: $62,119,979.
Total stock sales since 2020: $95,615.
Total stock option exercises since 2020: $258,779.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 55,914 | $16,436 | 240,691 | $0 |
| 2024 | 42,400 | $100,041 | 18,699 | $21,880 | 0 | $0 |
| 2023 | 715,698 | $1,778,483 | 1,208 | $3,515 | 14,292 | $19,293 |
| 2022 | 1,474,362 | $4,491,442 | 19,995 | $53,784 | 42,300 | $84,468 |
| 2021 | 311,111 | $6,999,997 | 0 | $0 | 117,272 | $155,018 |
| 2020 | 2,867,648 | $48,750,016 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 55,914 | $16,436 | 0 | $0 |
| 2025-06 | 0 | $0 | 0 | $0 | 240,691 | $0 |
| 2024-09 | 0 | $0 | 13,879 | $7,854 | 0 | $0 |
| 2024-06 | 42,400 | $100,041 | 0 | $0 | 0 | $0 |
| 2024-01 | 0 | $0 | 4,820 | $14,026 | 0 | $0 |
| 2023-12 | 605,686 | $1,462,894 | 0 | $0 | 0 | $0 |
| 2023-06 | 80,012 | $243,239 | 0 | $0 | 7,882 | $10,640 |
| 2023-03 | 30,000 | $72,350 | 0 | $0 | 6,410 | $8,653 |
| 2023-01 | 0 | $0 | 1,208 | $3,515 | 0 | $0 |
| 2022-12 | 80,000 | $240,950 | 0 | $0 | 0 | $0 |
| 2022-11 | 5,000 | $16,440 | 0 | $0 | 0 | $0 |
| 2022-10 | 0 | $0 | 0 | $0 | 27,343 | $36,912 |
| 2022-06 | 1,381,362 | $4,129,172 | 19,995 | $53,784 | 2,500 | $3,375 |
| 2022-04 | 0 | $0 | 0 | $0 | 3,000 | $31,920 |
| 2022-03 | 8,000 | $104,880 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 0 | $0 | 3,152 | $3,750 |
| 2022-01 | 0 | $0 | 0 | $0 | 6,305 | $8,511 |
| 2021-08 | 0 | $0 | 0 | $0 | 50,440 | $68,094 |
| 2021-07 | 0 | $0 | 0 | $0 | 28,372 | $38,302 |
| 2021-06 | 0 | $0 | 0 | $0 | 9,457 | $11,789 |
| 2021-02 | 0 | $0 | 0 | $0 | 29,003 | $36,833 |
| 2021-01 | 311,111 | $6,999,997 | 0 | $0 | 0 | $0 |
| 2020-09 | 2,867,648 | $48,750,016 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-01 | Renninger Robert (SVP, Finance and Accounting) | Sale | 2,897 | .29 | 851 |
| 2025-07-01 | Worthington Mark (General Counsel and CCO) | Sale | 8,526 | .29 | 2,506 |
| 2025-07-01 | Church Kevin (CHIEF SCIENTIFIC OFFICER) | Sale | 8,526 | .29 | 2,506 |
| 2025-07-01 | San Martin Javier (CHIEF MEDICAL OFFICER) | Sale | 10,842 | .29 | 3,187 |
| 2025-07-01 | Litton Mark James (President and CEO) | Sale | 25,123 | .29 | 7,386 |
| 2025-06-30 | Renninger Robert (SVP, Finance and Accounting) | Option Ex | 12,359 | .00 | 0 |
| 2025-06-30 | Worthington Mark (General Counsel and CCO) | Option Ex | 36,666 | .00 | 0 |
| 2025-06-30 | Church Kevin (CHIEF SCIENTIFIC OFFICER) | Option Ex | 36,666 | .00 | 0 |
| 2025-06-30 | San Martin Javier (CHIEF MEDICAL OFFICER) | Option Ex | 46,666 | .00 | 0 |
| 2025-06-30 | Litton Mark James (President and CEO) | Option Ex | 108,334 | .00 | 0 |
| 2024-09-05 | Worthington Mark (GENERAL COUNSEL) | Sale | 2,525 | .57 | 1,429 |
| 2024-09-05 | Lenington Rachel (COO and CDO) | Sale | 2,525 | .57 | 1,429 |
| 2024-09-05 | Church Kevin (CHIEF SCIENTIFIC OFFICER) | Sale | 2,525 | .57 | 1,429 |
| 2024-09-05 | Litton Mark James (President and CEO) | Sale | 5,032 | .57 | 2,848 |
| 2024-09-05 | Gengos Andrew (CFO and Chief Business Officer) | Sale | 1,272 | .57 | 719 |
| 2024-06-24 | Romano Kelly A | Buy | 27,400 | 2.42 | 66,171 |
| 2024-06-21 | Romano Kelly A | Buy | 15,000 | 2.26 | 33,870 |
| 2024-01-05 | Litton Mark James (Chief Executive Officer) | Sale | 4,820 | 2.91 | 14,026 |
| 2023-12-29 | Edelman Joseph (Director) | Buy | 163,954 | 2.38 | 390,210 |
| 2023-12-28 | Edelman Joseph (Director) | Buy | 409,598 | 2.44 | 999,419 |
| 2023-12-27 | Edelman Joseph (Director) | Buy | 32,134 | 2.28 | 73,265 |
| 2023-06-07 | Gengos Andrew (See Below) | Buy | 15,000 | 3.40 | 50,985 |
| 2023-06-05 | Gengos Andrew (See Below) | Buy | 45,000 | 3.00 | 135,180 |
| 2023-06-02 | Moebius Hans (Chief Medical Officer) | Option Ex | 7,882 | 1.35 | 10,640 |
| 2023-06-02 | Gengos Andrew (See Below) | Buy | 20,012 | 2.85 | 57,074 |
| 2023-03-30 | Pickering Grant (Director) | Buy | 15,000 | 2.47 | 37,050 |
| 2023-03-29 | Pickering Grant (Director) | Buy | 10,000 | 2.33 | 23,300 |
| 2023-03-29 | Johnson James A (Director) | Buy | 5,000 | 2.40 | 12,000 |
| 2023-03-24 | Church Kevin (Chief Scientific Officer) | Option Ex | 6,410 | 1.35 | 8,653 |
| 2023-01-05 | Gengos Andrew (See Below) | Sale | 1,208 | 2.91 | 3,515 |
| 2022-12-28 | Mileson Glenna (Chief Financial Officer) | Buy | 50,000 | 2.85 | 142,250 |
| 2022-12-02 | Romano Kelly A (Director) | Buy | 30,000 | 3.29 | 98,700 |
| 2022-11-15 | Moebius Hans (Chief Medical Officer) | Buy | 5,000 | 3.29 | 16,440 |
| 2022-10-28 | Church Kevin (Executive VP, Research) | Option Ex | 3,700 | 1.35 | 4,995 |
| 2022-10-13 | Moebius Hans (Chief Medical Officer) | Option Ex | 15,762 | 1.35 | 21,278 |
| 2022-06-30 | Edelman Joseph (Director) | Buy | 1,101,362 | 2.99 | 3,293,072 |
| 2022-06-29 | Edelman Joseph (Director) | Buy | 270,000 | 2.99 | 807,300 |
| 2022-06-28 | Moebius Hans (Chief Medical Officer) | Buy | 10,000 | 2.88 | 28,800 |
| 2022-06-23 | Worthington Mark (General Counsel) | Sale | 2,614 | 2.69 | 7,031 |
| 2022-06-23 | Lenington Rachel (Chief Operating Officer) | Sale | 4,193 | 2.69 | 11,279 |
| 2022-06-23 | Church Kevin (Executive VP, Research) | Sale | 2,614 | 2.69 | 7,031 |
| 2022-06-23 | Mileson Glenna (Chief Financial Officer) | Sale | 2,614 | 2.69 | 7,031 |
| 2022-06-23 | Litton Mark James (Chief Executive Officer) | Sale | 7,960 | 2.69 | 21,412 |
| 2022-06-08 | Church Kevin (Executive VP, Research) | Option Ex | 2,500 | 1.35 | 3,375 |
| 2022-04-11 | Mileson Glenna (Chief Financial Officer) | Option Ex | 3,000 | 10.64 | 31,920 |
| 2022-03-31 | Romano Kelly A (Director) | Buy | 8,000 | 13.11 | 104,880 |
| 2022-02-18 | Church Kevin (Executive VP, Research) | Option Ex | 3,152 | 1.19 | 3,750 |
| 2022-01-04 | Mileson Glenna (Chief Financial Officer) | Option Ex | 6,305 | 1.35 | 8,511 |
| 2021-08-17 | Litton Mark James (Chief Operating Officer) | Option Ex | 50,440 | 1.35 | 68,094 |
| 2021-07-21 | Moebius Hans (Chief Medical Officer) | Option Ex | 28,372 | 1.35 | 38,302 |
| 2021-06-10 | Mileson Glenna (Chief Financial Officer) | Option Ex | 6,305 | 1.35 | 8,511 |
| 2021-06-08 | Church Kevin (Vice President of Discovery) | Option Ex | 3,152 | 1.04 | 3,278 |
| 2021-02-03 | Fluke John M Jr (Director) | Option Ex | 29,003 | 1.27 | 36,833 |
| 2021-01-25 | Edelman Joseph (Director) | Buy | 311,111 | 22.50 | 6,999,997 |
| 2020-09-22 | Perceptive Life Sciences Master Fund Ltd (10% Owner) | Buy | 1,058,824 | 17.00 | 18,000,008 |
| 2020-09-22 | Edelman Joseph (Director) | Buy | 1,058,824 | 17.00 | 18,000,008 |
| 2020-09-18 | Wong Roderick | Buy | 750,000 | 17.00 | 12,750,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ATHA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Athira Pharma, Inc. (symbol ATHA, CIK number 1620463) see the Securities and Exchange Commission (SEC) website.